TO THE EDITOR
Ohno et al 1 have recently proposed their strategy for further increasing cure rates in acute promyelocytic leukemia (APL). As described by the authors, there is a common perception that extramedullary relapse including central nervous system (CNS) disease occurs more frequently in patients treated with all transretinoic acid (ATRA). In an analysis of patients enrolled into two consecutive studies by Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA), extramedullary leukemia occurred in 16 of 131 (12%) patients vs five of 94 (5%) patients treated with or without ATRA, respectively (P ¼ 0.08). The probabilities of extramedullary relapse were 4.5 and 3%, respectively (P ¼ 0.79), while the probabilities of CNS involvement were 0.6 and 2% (P ¼ 0.28). 2 In the JALSG studies, none of the patients treated in the pre-ATRA era had extramedullary relapse as compared to 10 of 121 (8%) patients treated with ATRA-containing regimens (P ¼ 0.063). 1 The incidence of CNS disease at relapse was also not significantly higher in the ATRA-treated patients (P ¼ 0.148). 1 Several other anecdotal reports of CNS disease after therapy with ATRA in patients with APL exist in the literature. 3 Breccia et al 4 have recently reported on six patients, including two asymptomatic patients in molecular remission, who were identified to have CNS disease after the group introduced the practice of routine lumbar puncture in all patients with a presentation high white cell count (WBC410 Â 10 9 /l). Several factors including prolongation of survival related to the ATRA-containing regimens, provision of a sanctuary site in the CNS related to poor penetration of blood/brain barrier by ATRA, and upregulation of adhesion molecules induced by ATRA have been suggested as contributing to this phenomenon. Similarly, an association with several clinical features, including an elevated WBC at diagnosis, presence of the PML/RAR bcr3 type and the microgranular morphology, and the development of ATRA syndrome have been reported. 3, 4 This has led to the above-mentioned strategy by the Italian group of obtaining CSF for molecular examination at the time of first remission in all patients with a presenting WBC410 Â 10 9 /l. 4 Extramedullary disease and, in particular, central nervous relapse of APL had been infrequently reported in patients treated prior to the availability of ATRA. 5 An association with treatment with ATRA has been suggested. However, in a review of 212 patients with APL presenting to the Leukemia department at the MD Anderson Cancer Center between April 1983 and August 2003, we have identified only three patients with CNS relapse after achieving a complete remission (two following ATRA and one with chemotherapy alone). The incidence of CNS relapse was two out of 135 (2%) for the ATRA-treated patients vs one out of 77 (1%) prior to ATRA (P ¼ 0.9). The presentation WBC for the two patients treated with ATRA were 1.7 Â 10 9 /l and 8.6 Â 10 9 /l as compared with the median presentation WBC of 4.3 Â 10 9 /l for the whole group. The patient treated with chemotherapy alone had a presenting WBC of 1.3 Â 10 9 /l. No other specific or unusual features were noted in these patients.
Ohno et al 1 recommend implementation of prophylactic use of intrathecal methotrexate and cytarabine as one of several strategies for further increasing the cure rate in APL, and in the Japanese APL studies at least one dose of intrathecal chemotherapy is routinely administered for CNS prophylaxis. However, the present data as well as the available literature do not appear to justify prophylactic CNS therapy in all patients with APL. It may be possible that meningeal infiltration occurs at the time of diagnosis in some patients and, due to the inability of drugs commonly used to treat APL (ATRA and anthracyclines) to cross the blood/brain barrier, CNS relapses occur without systemic failure. Furthermore, the omission of cytarabine from the more recent regimens may further contribute to this risk. Therefore, identification of predisposing features similar to those suggested by Breccia et al and their application in a risk-based strategy may be more appropriate. The leukemic blasts from two patients in the series by Breccia et al expressed CD56, a feature correlated to an inferior outcome by several groups. 6 Although no specific association between CD56 expression and CNS disease in APL has been reported, its expression has been reported to predict the occurrence of CNS disease in acute lymphoblastic leukemia (ALL).
7 Therefore, evaluation for CD56 expression should be considered in all patients at diagnosis, as is the practice in the current North American Intergroup APL study. CD56 expression was evaluated in the blast cells of two of our patients and was not detected. Finally, several reports of response of CNS disease to therapy with ATRA as well as chemotherapy exist, further limiting the potential benefit of a universal early-intervention strategy. 8 The elevated hemorrhagic risk at diagnosis in the majority of APL patients is likely to prevent lumbar puncture at presentation. Therefore, a plausible strategy is to perform lumbar puncture in first complete cytogenetic remission in patients deemed to be at a high risk, such as those with elevated WBC and perhaps those expressing CD56. They used semiquantitative RT-PCR technique to study the expression levels of ASPP members in a panel of paired normal and tumor RNA samples derived from breast cancer patients. The results showed that the expression levels of ASPP1 and ASPP2 were downregulated in 60% of human breast tumors expressing wild-type p53. Eight tumors expressing wild-type p53 overexpressed iASPP relative to their normal paired controls, whereas seven of these tumors showed normal levels of ASPP1 and ASPP2.
Wild-type p53 exists in 95% of leukemias. 5 How this kind of cancer arose despite its being in possession of intact, functional p53? The discovery of ASPP family might clear up this mystery. To understand the status of ASPP members in leukemia, we investigated the expression levels of ASPP members in three leukemia cancer cell lines HL-60, K562 and Jurkat (Table 1) . The results showed that the level of ASPP1 is downregulated and that of the iASPP is upregulated. Our results suggest that abnormal ASPP expression could be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular marker for diagnosis of leukemia. T stands for the mRNA expression level of tumor cell line and N for the mRNA expression level of normal blood monocytes.
